...
首页> 外文期刊>Journal of the American Veterinary Medical Association >Incidence of sterile hemorrhagic cystitis in dogs receiving cyclophosphamide orally for three days without concurrent furosemide as part of a chemotherapeutic treatment for lymphoma:57 cases (2007-2012)
【24h】

Incidence of sterile hemorrhagic cystitis in dogs receiving cyclophosphamide orally for three days without concurrent furosemide as part of a chemotherapeutic treatment for lymphoma:57 cases (2007-2012)

机译:口服环磷酰胺三天而未同时应用速尿作为淋巴瘤化疗药物的一部分的无菌性出血性膀胱炎发生率:57例(2007-2012年)

获取原文
获取原文并翻译 | 示例

摘要

Objective—To evaluate the incidence of sterile hemorrhagic cystitis (SHC) and other adverse effects in dogs following oral administration of the single-day, maximum-tolerated dose (MTD) of cyclophosphamide divided over 3 days as part of a multiagentchemotherapy protocol for treatment of lymphoma without concurrent administration of furosemide. Design—Retrospective case series. Animals—57 dogs. Procedures—Medical records were reviewed to identify dogs with lymphoma that underwent the described cyclophosphamide treatment. Information was obtained regarding sig-nalment, lymphoma stage, concurrent diseases, cyclophosphamide doses administered, adverse effects (including SHC), remission rates, and outcomes. The incidence of SHC was compared with that of literature-derived historical control groups that received the MTD of cyclophosphamide as a single, 1-day dose with or without furosemide treatment. Results—None of the 57 dogs developed SHC during the study period. Forty-seven of 57 (82%) dogs hadcomplete remission of lymphoma. Other adverse effects were uncommon and self-limiting; no dogs had myelosuppression, and only 5 had mild gastrointestinal effects. Incidence of SHC was significantly lower than that reported for historical control dogs that received cyclophosphamide as a single dose without furosemide (24/219) and was not significantly different from that for historical control dogs that received cyclophosphamide as a single dose with furosemide (2/139). Conclusions and Clinical Relevance—No dogs in this study had SHC following oral administration of the single-day MTD of cyclophosphamide divided over a 3-day period without furosemide administration. Further research is needed to confirm whether this method of cyclophosphamide administration is equivalent or superior to the current single-dose administration method.
机译:目的-评价环磷酰胺单日最大耐受剂量(MTD)连续三天的口服给药后,狗的无菌性出血性膀胱炎(SHC)的发生率和其他不良反应,这是多药治疗方案的一部分淋巴瘤未同时应用速尿。设计-回顾性案例系列。动物-57条狗。程序-查阅医学记录以鉴定接受了上述环磷酰胺治疗的淋巴瘤犬。获得了有关信号,淋巴瘤分期,并发疾病,环磷酰胺的给药剂量,不良反应(包括SHC),缓解率和预后的信息。将SHC的发生率与文献来源的历史对照组进行比较,后者接受环磷酰胺MTD作为单日1天剂量(接受或不接受呋塞米治疗)。结果-在研究期间,这57只狗中没有一只患有SHC。 57只狗中有47只(82%)的淋巴瘤完全缓解。其他不利影响不常见且自限。没有狗有骨髓抑制,只有5只具有轻度的胃肠道作用。 SHC的发生率显着低于单剂量不使用呋塞米的环磷酰胺(24/219)的历史对照犬的报告发生率,与单剂量并使用呋塞米的环磷酰胺的历史对照狗(2/9)的发生率无显着差异。 139)。结论与临床相关性:本研究中没有狗在口服环磷酰胺的单日MTD后连续3天不口服速尿时服用SHC。需要进一步的研究来确认这种环磷酰胺的给药方法是否等同于或优于目前的单剂量给药方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号